Aurobindo Pharma gets official action indicated classification from USFDA for its plant
New Delhi: Aurobindo Pharma has announced that the US Food and Drug Administration (FDA) classified the inspection of the company's oral solids formulation manufacturing facility of Unit VII as official action indicated (OAI).
"The company believes that this OAI classification will not have any material impact on the existing revenues or the supplies to our US business at this juncture," Aurobindo Pharma said in a BSE filing.
The company will work closely with the regulator to comprehensively address the issues.
Official Action Indicated means "objectionable conditions were found and regulatory administrative sanctions by FDA are indicated" during inspections. OAI means an FDA inspection revealed significant objectionable conditions or practices and action must be taken to address the issues.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd